# NCT05629585 (NCT05629585)

> A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05629585
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Breast Cancer
- Interventions: Dato-DXd; Durvalumab; Capecitabine; Pembrolizumab
- Enrollment: 1174
- Primary outcome: Invasive disease-free survival (iDFS) for Dato-DXd + durvalumab vs. ICT

## Commentary we found

- YouTube: 17
- Podcasts: 16
- X threads: 5
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct05629585

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05629585", "email": "<work email>"}; the inbox owner confirms by the emailed link.